Literature DB >> 382158

Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry.

T R Weihrauch, C F Förster, J Krieglstein.   

Abstract

Intraluminal manometry has been used in a series of five studies on healthy volunteers and patients, to examine the action of domperidone on lower oesophageal sphincter pressure (LOSP), on peristaltic contraction, amplitudes and on antral, pyloric and duodenal motility. Furthermore, the effect on gastric acid secretion, pH, secretory volume and serum gastrin levels was studied. It was found that domperidone increased LOSP significantly but was less effective in patients with symptomatic gastro-oesophageal reflux than in normal volunteers. The drug also increased the amplitude of oesophageal and duodenal peristalsis but had no effect on endogenous gastrin release or on gastric acid secretion. The results suggest that this drug may be useful in the treatment of gastro-oesophageal and gastroduodenal reflux. This potential benefit is enhanced by the absence of side effects even when given in high doses.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 382158

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  12 in total

Review 1.  Frontiers in functional dyspepsia.

Authors:  Noel R Fajardo; Filippo Cremonini; Nicholas J Talley
Journal:  Curr Gastroenterol Rep       Date:  2005-08

2.  On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.

Authors:  J Heykants; R Hendriks; W Meuldermans; M Michiels; H Scheygrond; H Reyntjens
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

3.  Lack of effect of metoclopramide and domperidone on esophageal peristalsis and esophageal acid clearance in reflux esophagitis. A randomized, double-blind study.

Authors:  L Grande; G Lacima; E Ros; J C García-Valdecasas; J Fuster; J Visa; C Pera
Journal:  Dig Dis Sci       Date:  1992-04       Impact factor: 3.199

4.  Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study.

Authors:  George P Karamanolis; Stylianos Panopoulos; Anastasios Karlaftis; Konstantinos Denaxas; Dimitrios Kamberoglou; Petros P Sfikakis; Spiros D Ladas
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

5.  On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats.

Authors:  J Heykants; A Knaeps; W Meuldermans; M Michiels
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

Review 6.  Functional dyspepsia. Current treatment recommendations.

Authors:  Gerald Holtmann; Nicholas J Talley
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 7.  Medical treatment of esophageal motility disorders.

Authors:  H D Allescher; W J Ravich
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

8.  Metoclopramide inhibits development of esophageal varices in rat model.

Authors:  M Ohta; M Hashizume; K Tanoue; K Ueno; K Komori; T Ishii; S Kitano; K Sugimachi
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

Review 9.  Domperidone. A review of its use in diabetic gastropathy.

Authors:  A Prakash; A J Wagstaff
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 10.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.